Impact Factor
Global reach, higher impact
Research Paper Reshaping immune cell distribution with mRNA noncationic lipid nanoparticles for overcoming neoadjuvant chemo-immunotherapy resistance Full text PDF
Research Paper CCR2 deficiency protects against doxorubicin-induced cardiac dysfunction through enhanced IL12B-dependent autophagy Full text PDF
Research Paper Magnetofection-mediated siRNA delivery ameliorates cartilage damage in Kashin-Beck disease via targeting SIRT3 and protecting primary cilia Full text PDF
Research Paper Clinically accessible drug-based nano-assemblies with self-targeting ability for NIR-II fluorescence imaging-guided surgery in triple-negative breast cancer Full text PDF
Research Paper Metabolic-Immune Reprogramming via CuZnS@BSA Nanoregulators to Overcome Resistance in Triple-Negative Breast Cancer Full text PDF
Research Paper Structure-based redesign enables clinical translation of CAIX-targeted theranostics in clear cell renal cell carcinoma Full text PDF
Issue 12; 2026
Founding Editor-in-Chief:
Prof. Xiaoyuan (Shawn) Chen, PhD
Profile
Theranostics publishes innovative research articles reflecting the fields of in vitro diagnostics and prognostics, in vivo molecular imaging, molecular therapeutics, image-guided therapy, biosensors, system biology and translational medicine, personalized medicine and a broad spectrum of biomedical research that can be applied to future theranostic applications.
- Theranostics is indexed by Science Citation Index (SCI) and MEDLINE. (Full index information)
- Full texts of articles in PubMed Central and Europe PMC. Abstracts in PubMed.
- (For NIH-funded researchers) Save time by submitting your paper to us - this journal is in full compliance with NIH Public Access Requirement.
Rationale: Since the therapeutic resistance of triple-negative breast cancer (TNBC) is mainly attributable to excessive glutathione (GSH) accumulation and its ‘cold’ immune landscape, we designed biomimetic CuZnS@BSA nanoregulators that exploit a pH-triggered ‘disarm-and-attack’ cascade, thereby initiating a well-defined, sequential therapeutic process in the acidic tumor microenvironment. Methods: Biomimetic CuZnS@BSA ...